CSTDs
While the chapter requires CSTD use when administering antineoplastic HDs (if the dosage form allows) and recommends CSTD use when compounding HDs, it simply makes sense to implement CSTDs for both processes. Clearly pharmacy has embraced this more expansive approach; in fact, CSTD adoption rates for compounding significantly exceed those for administration. Looking ahead, this market segment will remain busy as more facilities look to complete CSTD implementations to achieve chapter compliance.
CSTD adoptions in the pharmacy continue to outpace those on the units. Although the implementation increases over the past few years have been in the single digits, most pharmacies currently without this technology are exceedingly confident that they will have CSTDs in place by the 12/1 deadline. 96% of facilities predict that they will have CSTDs in the pharmacy by year end, and 91% expect that CSTDs will be in place on the units in the same timeframe.
For drug preparation, the leading CSTD vendor is BD, followed by Equashield, ICU Medical, and B. Braun. This market continues to expand, with new devices entering the market this year.
Click here to view a larger version of this Chart
For drug administration, the leading CSTD vendor is BD, followed by Equashield, ICU Medical, and B. Braun.
Click here to view a larger version of this Chart
Like what you've read? Please log in or create a free account to enjoy more of what www.pppmag.com has to offer.
Recent Popular Articles
Current Issue
